#071 $TLX in Hot Water Telix Faces SEC Heat Over Drug Development Disclosures

Telix Pharmaceuticals $TLX is facing a federal subpoena and a scorching class action lawsuit after allegedly misleading investors about its prostate cancer drug pipeline and FDA compliance. In this episode of Sue Wall Street, we dive into how missing trial data, shady supply chain claims, and a bombshell FDA rejection sent the stock tumbling. Ideal for biotech investors, legal watchers, and anyone tracking pharmaceutical accountability. Get the facts, not just the filings. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.